TRABTRAP Sarkom

{ "short_title": "TRABTRAP Sarkom", "data_mode": "900", "data_mode_number": "000002192", "official_title": "PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR \r\nTO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR \r\nREFRACTORY SOFT TISSUE SARCOMA (STS; 2nd LINE) ", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "second", "ctgov_number": null, "eudract_number": null, "general_contact_email": "oncostudy@ukdd.de", "general_contact_phone": "+49 351-4587666", "hauptpruefer_dd_name": "Dr. med. Stephan Richter", "description_laie_de": "VERGLEICHSSTUDIE VON TRABECTEDIN GEGEN TRABECTEDIN PLUS tTF-NGR; ZUM EINSCHLUSS VON TRABECTEDIN IN DEN TUMOR BEI PATIENTEN MIT METASTASIERTEM UND/ODER REFRAKT\u00c4REM WEICHTEILSARKOM (STS).", "description_laie_en": "COMPARATIVE STUDY OF TRABECTEDIN AGAINST TRABECTEDIN PLUS tTF-NGR; ON THE INCLUSION OF TRABECTEDIN IN THE TUMOR IN PATIENTS WITH METASTASIZED AND/OR REFRACTORY SECTOR SECTORS (STS).", "description_expert_de": "PHASE III STUDIE MIT TRABECTEDIN (T) VERSUS T PLUS tTF-NGR UM T INNERHALB DES TUMORS EINZUSCHLIE\u00dfEN BEI PATIENTEN MIT \r\nMETASTASIERTEN UND/ODER REFRAKT\u00c4REN WEICHTEILSARKOMEN (STS)", "description_expert_en": "PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR \r\nREFRACTORY SOFT TISSUE SARCOMA (STS)", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 9, "sub_cat_id": 43 }